| Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A KM White, R Rosales, S Yildiz, T Kehrer, L Miorin, E Moreno, S Jangra, ... Science 371 (6532), 926-931, 2021 | 309 | 2021 |
| Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis S Yildiz, B Mazel-Sanchez, M Kandasamy, B Manicassamy, M Schmolke Microbiome 6, 1-17, 2018 | 239 | 2018 |
| The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera R Rathnasinghe, S Jangra, A Cupic, C Martínez-Romero, LCF Mulder, ... MedRxiv, 2021 | 114 | 2021 |
| CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity B Gungor, FC Yagci, G Tincer, B Bayyurt, E Alpdundar, S Yildiz, M Ozcan, ... Science translational medicine 6 (235), 235ra61-235ra61, 2014 | 97 | 2014 |
| TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation JSY Ho, BWY Mok, L Campisi, T Jordan, S Yildiz, S Parameswaran, ... Cell 184 (10), 2618-2632. e17, 2021 | 91 | 2021 |
| SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice ES Winkler, RE Chen, F Alam, S Yildiz, JB Case, MB Uccellini, ... Journal of virology 96 (1), e01511-21, 2022 | 70 | 2022 |
| Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target E Yángüez, A Hunziker, MP Dobay, S Yildiz, S Schading, E Elshina, ... Nature communications 9 (1), 3679, 2018 | 53 | 2018 |
| Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis T Kehrer, A Cupic, C Ye, S Yildiz, M Bouhaddou, NA Crossland, ... Cell Host & Microbe 31 (10), 1668-1684. e12, 2023 | 47 | 2023 |
| Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell‐penetrating peptide or combined with CpG S Yildiz, E Alpdundar, B Gungor, T Kahraman, B Bayyurt, I Gursel, ... European journal of immunology 45 (4), 1170-1179, 2015 | 44 | 2015 |
| Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19 JF Varona, P Landete, JA Lopez-Martin, V Estrada, R Paredes, ... Life science alliance 5 (4), 2022 | 33 | 2022 |
| Influenza A viruses limit NLRP3‐NEK7‐complex formation and pyroptosis in human macrophages I Boal‐Carvalho, B Mazel‐Sanchez, F Silva, L Garnier, S Yildiz, ... EMBO reports 21 (12), e50421, 2020 | 32 | 2020 |
| Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera R Rathnasinghe, S Jangra, C Ye, A Cupic, G Singh, C Martínez-Romero, ... Nature Communications 13 (1), 3921, 2022 | 29 | 2022 |
| Respiratory tissue-associated commensal bacteria offer therapeutic potential against pneumococcal colonization S Yildiz, JP Pereira Bonifacio Lopes, M Bergé, V González-Ruiz, D Baud, ... Elife 9, e53581, 2020 | 29 | 2020 |
| Menage a trois: virus, host, and microbiota in experimental infection models B Mazel-Sanchez, S Yildiz, M Schmolke Trends in microbiology 27 (5), 440-452, 2019 | 25 | 2019 |
| Modeling SARS-CoV-2: comparative pathology in rhesus macaque and Golden Syrian hamster models S Choudhary, I Kanevsky, S Yildiz, RS Sellers, KA Swanson, T Franks, ... Toxicologic pathology 50 (3), 280-293, 2022 | 24 | 2022 |
| Fecal components modulate human astrovirus infectivity in cells and reconstituted intestinal tissues FJ Pérez-Rodriguez, G Vieille, L Turin, S Yildiz, C Tapparel, L Kaiser Msphere 4 (6), 10.1128/msphere. 00568-19, 2019 | 13 | 2019 |
| Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants JA Duty, T Kraus, H Zhou, Y Zhang, N Shaabani, S Yildiz, N Du, A Singh, ... Med 3 (10), 705-721. e11, 2022 | 10 | 2022 |
| Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization JF Varona, P Landete, JA Lopez-Martin, V Estrada, R Paredes, ... MedRxiv, 2021.05. 25.21257505, 2021 | 9 | 2021 |
| RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine S Jangra, G Laghlali, A Choi, R Rathnasinghe, Y Chen, S Yildiz, ... Frontiers in immunology 13, 974016, 2022 | 8 | 2022 |
| H19 influenza A virus exhibits species-specific MHC class II receptor usage U Karakus, I Mena, J Kottur, SS El Zahed, R Seoane, S Yildiz, L Chen, ... Cell Host & Microbe, 2024 | 4 | 2024 |
